comparemela.com

Latest Breaking News On - Greenfire bio - Page 1 : comparemela.com

Slone Partners Places Gayarthri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics

South Riding, VA (PRWEB) February 08, 2023 Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies,

Hyderabad
Andhra-pradesh
India
Texas
United-states
Greenfire-bio
Linkedin-juvena
Edward-moler
Hanadie-yousef
Gayathri-swaminath
Eddie-moler
Tara-kochis

Slone Partners Places Gayathri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics

South Riding, VA (PRWEB) February 08, 2023 Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies,

Hyderabad
Andhra-pradesh
India
Texas
United-states
Greenfire-bio
Linkedin-juvena
Edward-moler
Hanadie-yousef
Gayathri-swaminath
Eddie-moler
Tara-kochis

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

/PRNewswire/ Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The.

United-states
Texas
American
Greenfire-bio
Zhen-lu
Robert-bast
Steve-morris
Bajit-gill
World-cancer-research-fund-international
Linkedin
University-of-texas-md-anderson-cancer-center
Facebook

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

/PRNewswire/ Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on.

United-states
Texas
American
Greenfire-bio
Siqing-fu
Bajit-gill
Linkedin
University-of-texas-md-anderson-cancer-center
Twitter
Prnewswire-greenfire-bio
Md-anderson-cancer-center
World-cancer-research-fund-international

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

/PRNewswire/ Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on.

United-states
Texas
American
Greenfire-bio
Siqing-fu
Bajit-gill
Linkedin
University-of-texas-md-anderson-cancer-center
Twitter
Prnewswire-greenfire-bio
Md-anderson-cancer-center
World-cancer-research-fund-international

vimarsana © 2020. All Rights Reserved.